Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial

International Journal of Cancer

Volumn 127, Issue 7, 2010, Pages 1650-1659

  Murtola, Teemu J ^a,b   Tammela, Teuvo L J ^c,d   Määttänen, Liisa ^e   Huhtala, Heini ^a   Platz, Elizabeth A ^f   Ala Opas, Martti ^g   Stenman, Ulf Håkan ^h   Auvinen, Anssi ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b Central Finland Central Hospital   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e FINNISH CANCER REGISTRY   (Finland)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Epidemiology; Incidence; Prostate cancer; Prostate specific antigen; Statins

Indexed keywords

ACIPIMOX; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FINLAND; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; EARLY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; PREVALENCE; PROSTATE TUMOR; RISK; RISK ASSESSMENT;

AGED; EARLY DETECTION OF CANCER; FINLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RISK; RISK ASSESSMENT;

EID: 77955875455     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25165     Document Type: Article

References (27)

1. Murtola TJ, Visakorpi T, Lahtela J, Syvälä H, Tammela TLJ. Statins and prostate cancer prevention: where are we now and future directions. Nat Clin Pract Urol 2008;5:376-87.
2. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36. (Pubitemid 351166615)
3. Boudreau DM, Yu O, Buist DS, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008;19:767-74.
4. Olsen JH, Johansen C, Sørensen HT, McLaughlin JK, Mellemkjaer L, Steffensen FH, Fraumeni JF, Jr. Lipid-lowering medication and risk of cancer. J Clin Epidemiol 1999;52:167-9.
5. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168:250-60.
6. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100:134-9.
7. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM;West of Scotland Coronary Prevention Study Group.Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86.
8. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54.
9. Andriole GL, Crawford ED, Grubb RL, III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-19.
10. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
11. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta Oncol 1994;33:365-9.
12. Finne P, Stenman UH, Määttänen L, Mäkinen T, Tammela TL, Martikainen P, Ruutu M, Ala-Opas M, Aro J, Karhunen PJ, Lahtela J, Rissanen P, et al. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003;92:22-6.
13. Martikainen J, Rajaniemi S. Drug reimbursement systems in EU Member States, Iceland and Norway. The Social Insurance Institution, Finland, Social security and health reports 54, 2002. (Accessed November 25, 2009, at http://www.kela.fi/in/internet/liite.nsf/ABID/030303101726PN/$File/ Drug-reimbursement.pdf?openElement.)
14. World Health Organization. ATC/DDD index database. (Accessed November 25, 2009, at http://www.whocc.no/atcddd/indexdatabase/index.php?query=C10A.)
15. Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, Nakamura N. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008;31:930-1.
16. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006;164:978-83.
17. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate specific antigen levels. J Natl Cancer Inst 2008;100:1511-18.
18. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005;173:1923-5.
19. Mondul A, Selvin E, DeMarzo A, Platz E. Statin drugs and PSA concentration in the National Health and Nutrition Examination Survey (NHANES) 2001-2004. Abstract #B127. Presented at the Sixth AACR International Conference on Frontiers in Cancer Prevention Research, Dec 5-8,2007, Philadelphia, PA.
20. Statistics Finland. Finland in figures: population structure. (Accessed November 25, 2009, at http://www.stat.fi/til/vaerak/index-en.html.)
21. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol 2005;15:167-71.
22. Wu K. Hu FB, Willett WC, Giovannucci E. Dietary patterns and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 2006;15:167-71.
23. Martikainen J, Rajaniemi S, Klaukka T. Lääkekorvaukset 1990-luvulla. Tausta ja kehitys. Sosiaali- ja terveysturvan selosteita 11/1999, Helsinki: Kela, 1999.
24. Murtola TJ, Tammela TLJ, Lahtela J, Auvinen A. Serum lipid-lowering drugs and prostate cancer risk - a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-32.
25. Murtola TJ, Pennanen P, Syvälä H, Bläuer M, Ylikomi T, Tammela TL. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial Cells at therapeutic concentrations. Prostate 2009;69:1017-23.
26. Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 2008;19:113-21.
27. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 2008;123:1693-8.